Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2012)
MACH14 Investigators. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients
K. Dooley, P. Sayre, J. Borland, E. Purdy, Shuguang Chen, I. Song, A. Peppercorn, Stephanie Everts, S. Piscitelli, C. Flexner (2013)
Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 62
B. Genberg, I. Wilson, D. Bangsberg, J. Arnsten, K. Goggin, R. Remien, J. Simoni, R. Gross, N. Reynolds, M. Rosen, Honghu Liu (2012)
Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North AmericaAIDS, 26
H. Stellbrink, J. Reynes, A. Lazzarin, E. Voronin, F. Pulido, F. Felizarta, S. Almond, M. Clair, Nancy Flack, S. Min (2013)
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging studyAIDS (London, England), 27
C. Duncombe, A. Ball, C. Passarelli, G. Hirnschall (2013)
Treatment 2.0: catalyzing the next phase of treatment, care and supportCurrent Opinion in HIV and AIDS, 8
Papers of particular interest, published within the annual period of review
C. Flexner (2007)
HIV drug development: the next 25 yearsNature Reviews Drug Discovery, 6
L. Else, A. Jackson, R. Puls, A. Hill, P. Fahey, E. Lin, A. Amara, M. Siccardi, V. Watson, J. Tjia, S. Emery, S. Khoo, D. Back, M. Boffito (2011)
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 StudyAntimicrobial Agents and Chemotherapy, 56
N. Padian, S. McCoy, S. Karim, N. Hasen, Julia Kim, M. Bartoš, E. Katabira, S. Bertozzi, B. Schwartländer, M. Cohen (2011)
HIV prevention transformed: the new prevention research agendaThe Lancet, 378
Myron Cohen, Ying Chen, M. McCauley, T. Gamble, Mina Hosseinipour, N. Kumarasamy, James Hakim, J. Kumwenda, Beatriz Grinsztejn, J. Pilotto, S. Godbole, Sanjay Mehendale, S. Chariyalertsak, B. Santos, Kenneth Mayer, I. Hoffman, S. Eshleman, E. Piwowar-Manning, Lei Wang, J. Makhema, Lisa Mills, Guy Bruyn, Ian Sanne, Joseph Eron, J. Gallant, D. Havlir, S. Swindells, Heather Ribaudo, V. Elharrar, David Burns, T. Taha, Karin Nielsen-Saines, D. Celentano, Max Essex, Thomas Fleming (2011)
Prevention of HIV-1 infection with early antiretroviral therapy.The New England journal of medicine, 365 6
K. Crawford, D. Ripin, Andrew Levin, Jennifer Campbell, C. Flexner (2012)
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.The Lancet. Infectious diseases, 12 7
J. Robertson, J. Feinberg (2012)
Darunavir: a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infectionExpert Opinion on Pharmacotherapy, 13
(2013)
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization
P. Ruane, E. Dejesus, D. Berger, M. Markowitz, Lijie Zhong, S. Ramanathan, M. Rhee (2013)
Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 63
F. Tanser, T. Bärnighausen, E. Grapsa, J. Zaidi, M. Newell (2013)
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South AfricaScience, 339
REVIEW URRENT Treatment optimization: an outline for PINION future success a b c Charles Flexner , Ben Plumley , and David H. Brown Ripin Purpose of review In this issue of Current Opinion, the Guest Editors and their colleagues provide a comprehensive overview of current activities aimed at optimizing global HIV treatment. In this introduction, we outline current goals and approaches that will be described in more detail elsewhere in this issue. Recent findings Two recent conferences, the first and second Conference on Antiretroviral Drug Optimization (CADO), brought together experts from academia, governments, foundations, the pharmaceutical industry, and community activists to develop a global HIV-treatment research agenda for the coming decade focused on better therapies and how to make them accessible to a broader population of people living with HIV. Important recommendations included a focus on more efficient process chemistry for antiretroviral drugs, investigation of antiretroviral dose reduction as a possible optimization strategy, recognition of the increasing importance of concurrent infections and comorbidities especially tuberculosis and aging-related diseases, and identifying a highly effective and affordable nontoxic, once-daily fixed-dose combination regimen for first-line treatment. Summary HIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety,
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Nov 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.